2 Reasons to Sell TXG and 1 Stock to Buy Instead
What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many ...
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with ...
10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings
Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports. A number of ...
10x Genomics gets injunction against Parse Biosciences' ATAC Products
Genomics announced that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences.
10x Genomics price target lowered to $15 from $20 at Citi
Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the ...
Investing11d
10x Genomics secures injunction against Parse Biosciences
PLEASANTON, Calif. - In a significant development in the biotechnology patent landscape, 10x Genomics Inc. (NASDAQ:TXG), currently valued at $1.2 billion, has successfully obtained a worldwide ...
Morningstar11d
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.